Correlation of CLEC1B haplotypes with plasma levels of soluble CLEC-2 in healthy individuals
- PMID: 33251920
- DOI: 10.1080/09537104.2020.1849601
Correlation of CLEC1B haplotypes with plasma levels of soluble CLEC-2 in healthy individuals
Abstract
Binding of podoplanin to the C-type lectin-like receptor 2 (CLEC-2) promotes platelet activation and soluble CLEC-2 (sCLEC-2) is shed from activated platelets. The role of sCLEC-2 in the plasma is unknown. The expression level and plasma concentration of sCLEC-2 could be affected by variants of the corresponding gene, CLEC1B. Here, we genotyped SNVs in the promoter and coding region of CLEC1B and determined plasma levels of sCLEC-2 in healthy individuals. We genotyped 516 healthy blood donors for 7 SNVs (rs10505743, rs11053538, rs4764178, rs76016091, rs2273986, rs2273987, rs521040) by using PCR methods and calculated haplotypes from the SNV genotypes. For 313 of the donors we measured the sCLEC-2 concentration in EDTA plasma samples by using a commercial ELISA. SNV typing revealed allele frequencies comparable to database information. None of the SNVs showed significant correlation with sCLEC-2 plasma levels. Haplotype analysis indicated 6 haplotypes with frequencies >1% and haplotype h3 was the most frequent (33.8%). Donors homozygous for h3 (n = 37) showed significantly lower sCLEC-2 plasma levels (median 0.95 ng/mL) than donors being h3 negative or heterozygous (n = 276; 1.44 ng/mL; p = .0203). We found that the sCLEC-2 plasma concentration is variable in healthy individuals and the CLEC1B genotype contributes to the expression level.
Keywords: C-type lectin-like receptor 2; CLEC1B variants; plasma marker; soluble CLEC-2.
Similar articles
-
C-Type Lectin-like Receptor 2 Expression Is Decreased upon Platelet Activation and Is Lower in Most Tumor Entities Compared to Healthy Controls.Cancers (Basel). 2023 Nov 22;15(23):5514. doi: 10.3390/cancers15235514. Cancers (Basel). 2023. PMID: 38067218 Free PMC article.
-
Measurement of soluble C-type lectin-like receptor 2 in human plasma.Platelets. 2015;26(8):711-9. doi: 10.3109/09537104.2015.1021319. Epub 2015 Apr 9. Platelets. 2015. PMID: 25856065
-
Development of an automated chemiluminescence enzyme immunoassay for the measurement of soluble C-type lectin-like receptor 2 (sCLEC-2) and molecular forms of sCLEC-2 measured in patient plasma.Platelets. 2024 Dec;35(1):2420949. doi: 10.1080/09537104.2024.2420949. Epub 2024 Oct 30. Platelets. 2024. PMID: 39475059
-
Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin.Blood. 2019 Nov 28;134(22):1912-1918. doi: 10.1182/blood.2019001388. Blood. 2019. PMID: 31778548 Review.
-
[A role of the platelet receptor CLEC-2 in lymphangiogenesis and its clinical application].Rinsho Byori. 2013 Apr;61(4):318-27. Rinsho Byori. 2013. PMID: 23855188 Review. Japanese.
Cited by
-
C-Type Lectin-like Receptor 2 Expression Is Decreased upon Platelet Activation and Is Lower in Most Tumor Entities Compared to Healthy Controls.Cancers (Basel). 2023 Nov 22;15(23):5514. doi: 10.3390/cancers15235514. Cancers (Basel). 2023. PMID: 38067218 Free PMC article.
-
CLEC14A was up-regulated in hepatocellular carcinoma and may function as a potential diagnostic biomarker.Clinics (Sao Paulo). 2022 May 13;77:100029. doi: 10.1016/j.clinsp.2022.100029. eCollection 2022. Clinics (Sao Paulo). 2022. PMID: 35576868 Free PMC article.
-
Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice.Front Endocrinol (Lausanne). 2022 Nov 7;13:995007. doi: 10.3389/fendo.2022.995007. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36419767 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources